FDA-approved Product
Therapy Areas
Sanofi’s focus in transplant centers on managing chronic graft versus host disease (cGVHD) following an allogenic hematopoietic stem cell transplant
Educational Resources
Chronic Graft-Versus-Host Disease
GVHD Backgrounder
Overview of chronic graft-versus-host disease
ROCKreal: Belumosudil vs BAT US Population (EBMT 2025) PRO-1
Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the US population
Sanofi does not review or control the content of non-Sanofi websites.
Engage with Sanofi Payer Medical
Explore Other Therapy Areas
Immunology and Inflammation Resources
Neurology Resources
Oncology Resources
Rare Blood Disorders Resources
Member Engagement and Population Health Resources
Rare Diseases
Type 1 Diabetes
